OCS vs iReadMore

OCS-Plus provides health professionals with a brief cognitive assessment focussed on memory and executive attention. OCS-Plus was developed by the Translational Neuropsychology Research Group at the University of Oxford. The tool has been standardised, normed and validated (Demeyere et al 2021). The tool is currently undergoing further research for validity of use in specific clinical groups. The tool is not for self-assessment. Instead, a health professional assessor administers the screen to respondents to investigate domain-general cognitive impairments, with a specific focus on memory and executive attention. The tool contains multiple easy to administer tests and instructions are provided for each test. Normative data is provided for three age groups : under 60, between 60 and 70, and older than 70 and respondent performance is automatically compared to established normative cut offs. In order to activate the app for use, registration is required. There is no cost for the standard app version where data is not uploaded. Where data upload is required, an administration fee, as well as a collaboration agreement and datasharing agreement is required to be put in place.

iReadMore is a new reading therapy for improving single word reading ability. It is for people with an acquired reading disorder (alexia) or aphasia due to a stroke, brain injury or dementia. Start your 7 day free trial now! iReadMore Features: Adaptive Algorithm - iReadMore adapts to your abilities, keeping the therapy relevant and challenging. Self-led Therapy - iReadMore allows you to be in control of your own therapy with unlimited access. Science-Driven and Clinically-Proven Results - All of our therapies are developed through years of dedicated research at University College London by a team of scientists and clinicians. Integrated Feedback - Complete reading tests and see your own progress. iReadMore Research Summary: - iReadMore therapy has been tested in two clinical trials. It was shown to improve reading ability in people with pure alexia (Woodhead et al., 2013) and central alexia (Woodhead et al., 2018) - In the clinical trial of iReadMore for central alexia (the most common form of acquired reading disorder), the average improvement in reading accuracy was 8.7% for trained words. Three months after finishing the therapy, users still had significantly better reading ability than before they started. - Anonymised results from the app will be collected to test how effective the app is and to improve our understanding of reading rehabilitation. For more information and help getting started with iReadMore, please visit: https://www.ucl.ac.uk/icn/research/research-groups/neurotherapeutics/therapy-apps/ireadmore-app If you have any other questions, please email us at ireadmore@ucl.ac.uk iReadMore is a Class I CE marked medical device.